Tradestie Institutional Equity Comparison Engine
CRMD vs DSGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while DSGN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRMD trades at 29.5x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus DSGN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRMD sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
CRMD 29.5x vs DSGN N/M Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs +0.0%
Momentum & Technical Winner
DSGN
1Y -58.2% vs +33.3% ยท 52W Pos 1% vs 29%
Options & Structure Winner
DSGN
BREAKDOWN (22nd %ile IV) vs BREAKDOWN (13th %ile IV)
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap
$370.6M
1M Return
-36.38%
1Y Return
-58.23%
Forward P/E
29.5x
Unified AI Score
55.5 / 100
HOLD
Tech 60.0
Fund 62.0
Flow 70.0
Mom 55.0
DSGN
NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.82
-0.96% 1D
Market Cap
$670.5M
1M Return
-7.66%
1Y Return
+33.31%
Forward P/E
N/M
Unified AI Score
45.6 / 100
HOLD
Tech 44.0
Fund 55.0
Flow 60.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRMD -58.23%
DSGN +33.31%
Spread: +91.54 pp (DSGN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | DSGN Revenue | CRMD Op. Margin | DSGN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -9997.4% | N/A | CRMD |
| FY2018 | $0M | N/A | -6250.4% | N/A | CRMD |
| FY2019 | $0M | N/A | -7416.3% | N/A | CRMD |
| FY2020 | $0M | $0M | -11378.4% | -3685.8% | DSGN |
| FY2021 | $0M | N/A | -15417.5% | N/A | CRMD |
| FY2022 | $0M | N/A | -46819.9% | N/A | CRMD |
| FY2024 | $40M | N/A | -51.4% | N/A | CRMD |
| FY2025 | $310M | N/A | 48.2% | N/A | CRMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRMD | DSGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $370.6M | $670.5M | Larger Scale | DSGN |
| Trailing P/E Ratio Valuation | 2.4x | N/M | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | 29.5x | N/M | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | -47.7% | +0.0% | Higher Growth | DSGN |
| Operating Margin (TTM) Profitability | 41.0% | 0.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 15.5% | 0.0% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | 15.3% | -36.9% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 1% ($5โ$13) | 29% ($7โ$17) | Stronger Trend | DSGN |
| Beta / 30D Volatility Risk Regime | 1.22ฮฒ ยท 103% Vol | 1.33ฮฒ ยท 60% Vol | Lower Realized Risk | DSGN |
| Unified Institutional Score Composite Signal | 55.5 / 100 (HOLD) | 45.6 / 100 (HOLD) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRMD vs DSGN Buy Guide
CRMD
BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
DSGN
BREAKDOWN
140d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRMD nor DSGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.